Lessons learnt from human papillomavirus (HPV) vaccination in 45 low- and middleincome countries

PLoS ONE

Volumn 12, Issue 6, 2017, Pages

  Gallagher, Katherine E ^a,b   Howard, Natasha ^a   Kabakama, Severin ^b   Mounier Jack, Sandra ^a   Griffiths, Ulla K ^a   Feletto, Marta ^c   Burchett, Helen E D ^a   LaMontagne, D Scott ^c   Watson Jones, Deborah ^a,b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b National Institute for Medical Research   (Tanzania)

^c PATH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; FOLLOW UP; HEALTH CARE DELIVERY; HEALTH CARE FACILITY; HUMAN; INFORMED CONSENT; LOW INCOME COUNTRY; MEDICAL DOCUMENTATION; MIDDLE INCOME COUNTRY; PAPILLOMAVIRUS INFECTION; POPULATION RESEARCH; PRACTICE GUIDELINE; REFRESHER COURSE; SEMI STRUCTURED INTERVIEW; SYSTEMATIC REVIEW (TOPIC); TEACHER; UNSPECIFIED SIDE EFFECT; WORLD HEALTH ORGANIZATION; ADOLESCENT; DEVELOPING COUNTRY; FEMALE;

ADOLESCENT; DEVELOPING COUNTRIES; FEMALE; HUMANS; PAPILLOMAVIRUS VACCINES;

EID: 85020289207     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0177773     Document Type: Article

References (90)

1. IARC. GLOBOCAN 2012. Cervical Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012. Available at: http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx.
2. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006; 24 Suppl 3:S3/11-25. Epub 2006/09/05. S0264-410X(06)00684-0 [pii] https://doi.org/10.1016/j.vaccine.2006.05.111 PMID: 16949997.
3. Ott JJ, Ullrich A, Mascarenhas M, Stevens GA. Global cancer incidence and mortality caused by behavior and infection. Journal of Public Health. 2011; 33(2):223-33. https://doi.org/10.1093/pubmed/fdq076 PMID: 20935133
4. Peters LM, Soliman AS, Bukori P, Mkuchu J, Ngoma T. Evidence for the need of educational programs for cervical screening in rural Tanzania. J Cancer Educ. 2010; 25(2):153-9. Epub 2010/03/06. https://doi.org/10.1007/s13187-009-0018-9 PMID: 20204578;
5. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012; 30 Suppl 5:F123-38. Epub 2012/12/05. https://doi.org/10.1016/j.vaccine. 2012.04.108 PMID: 23199956.
6. Bosch FX, Broker TR, Forman D, Moscicki A-B, Gillison ML, Doorbar J, et al. Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine. 2013; 31, Supplement 5(0):F1-F31. http://dx.doi.org/10.1016/j.vaccine.2013.10.001.
7. Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. The New England journal of medicine. 2015; 372(8):711-23. Epub 2015/02/19. https://doi.org/10.1056/NEJMoa1405044 PMID: 25693011.
8. WHO. Human papillomavirus vaccines: WHO position paper. Wkly Epidemiol Rec. 2009; 15:118-31.
9. Merck & Co., Inc. GARDASIL Access Program,. Corporate Responsibility Report 2014. Key Initiatives: GARDASIL Access Program. http://www.merckresponsibility.com/access-to-health/key-initiatives/gardasil-access-program/2016 [cited 2016 04 February].
10. Gavi Alliance. Supplementary guidelines for human papillomavirus (HPV) vaccine demonstration project applications in 2015. Gavi Alliance, 2014.
11. Cervical Cancer Action. Cervical Cancer Action Progress maps; August 2015; http://www.cervicalcanceraction.org/comments/comments3.php 2015 [cited 2015 8th December].
12. World Health Organization. Monitoring the coverage and impact of human papillomavirus vaccine- report of WHO meeting, November 2009. Releve epidemiologique hebdomadaire/Section d'hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record/Health Section of the Secretariat of the League of Nations. 2010;85(25):237-43.
13. World Health Organization. HPV Vaccine Communication: Special Considerations for a unique vaccine. World Health Organization, 2013.
14. UNESCO Institute of Statistics. Education: Enrolment by level of education: Primary. August 2015 release http://data.uis.unesco.org/Index.aspx?queryid=128
15. Dorji T, Tshomo U, Phuntsho S, Tamang TD, Tshokey T, Baussano I, et al. Introduction of a National HPV vaccination program into Bhutan. Vaccine. 2015; 33(31):3726-30. Epub 2015/06/10. https://doi.org/10.1016/j.vaccine.2015.05.078 PMID: 26057136.
16. Herrero R, Gonzalez P, Markowitz LE. Present status of human papillomavirus vaccine development and implementation. The Lancet Oncology. 2015; 16(5):e206-e16. http://dx.doi.org/10.1016/S1470-2045%2814%2970481-4. PMID: 25943065.
17. Hanson CM, Eckert L, Bloem P, Cernuschi T. Gavi HPV programs: Application to implementation. PMID: 26343194. 2015; 3(2):408-19. http://dx.doi.org/10.3390/vaccines3020408.
18. Sankaranarayanan R. HPV vaccination: the most pragmatic cervical cancer primary prevention strategy. (World Report on Women's Health 2015: The unfinished agenda of women's reproductive health.). International Journal of Gynecology & Obstetrics. 2015;131(Suppl. 1):S33-S5.
19. Ladner J, Besson MH, Hampshire R, Tapert L, Chirenje M, Saba J. Assessment of eight HPV vaccination programs implemented in lowest income countries. BMC public health. 2012; 12:370. http://dx.doi.org/10.1186/1471-2458-12-370. PMID: 22621342.
20. Ladner J, Besson MH, Rodrigues M, Audureau E, Saba J. Performance of 21 HPV vaccination programs implemented in low and middle-income countries, 2009-2013. BMC public health. 2014; 14:670. Epub 2014/07/02. https://doi.org/10.1186/1471-2458-14-670 PMID: 24981818;
21. Adams M, Jasani B, Fiander A. Human papilloma virus (HPV) prophylactic vaccination: Challenges for public health and implications for screening. Vaccine. 2007; 25(16):3007-13. http://dx.doi.org/10.1016/j.vaccine.2007.01.016. PMID: 17292517.
22. Grover S, Raesima M, Bvochora-Nsingo M, Chiyapo SP, Balang D, Tapela N, et al. Cervical cancer in Botswana: Current state and future steps for screening and treatment programs. Frontiers in Oncology. 2015; 5 (NOV) (no pagination)(239). http://dx.doi.org/10.3389/fonc.2015.00239.
23. Ramogola-Masire D. Establishing a cervical cancer prevention service in Botswana. International Journal of Gynecology and Obstetrics. 2015; 131:E18.
24. Raesima MM, Forhan SE, Voetsch AC, Hewitt S, Hariri S, Wang SA, et al. Human Papillomavirus Vaccination Coverage Among School Girls in a Demonstration Project-Botswana, 2013. Mmwr. 2015; Morbidity and mortality weekly report. 64(40):1147-9. http://dx.doi.org/10.15585/mmwr.mm6440a5.
25. Fregnani JHTG, Carvalho AL, Eluf Neto J, Ribeiro KdCB, Kuil LdM, Silva TAd, et al. A school-based human papillomavirus vaccination program in Barretos, Brazil: final results of a demonstrative study. PloS one. 2013; 8(4). http://dx.doi.org/10.1371/journal.pone.0062647.
26. Baker ML, Figueroa-Downing D, Chiang EDdO, Villa L, Baggio ML, Eluf-Neto J, et al. Paving pathways: Brazil's implementation of a national human papillomavirus immunization campaign. Revista Panamericana de Salud Publica/Pan American Journal of Public Health. 2015; 38(2):163-6. PMID: 26581058.
27. Chiang EDdO, Baker ML, Figueroa-Downing D, Baggio ML, Villa L, Eluf Neto J, et al. "THOSE WHO LOVE, VACCINATE": PARENTAL PERCEPTIONS OF HPV VACCINATION. 2015. 2015; 25(3):10. Epub 2015-10-25. https://doi.org/10.7322/jhgd.106013
28. Kury CM, Kury MM, Silva RM, Oliveira FA, de Moraes JC, De Moraes JG, et al. Implementation of the quadrivalent vaccine against HPV in the Municipality of Campos dos Goytacazes, Brazil-A combination of strategies to increase immunization coverage and early reduction of genital warts. Trials in Vaccinology. 2013; 2:19-24.
29. Jauregui B, Sinha A, Clark AD, Bolanos BM, Resch S, Toscano CM, et al. Strengthening the technical capacity at country-level to make informed policy decisions on new vaccine introduction: Lessons learned by PAHO's ProVac Initiative. Vaccine. 2011; 29(5):1099-106. http://dx.doi.org/10.1016/j.vaccine.2010.11.075. PMID: 21144916
30. Ayissi CA, Wamai RG, Oduwo GO, Perlman S, Welty E, Welty T, et al. Awareness, acceptability and uptake of human papilloma virus vaccine among Cameroonian school-attending female adolescents. Journal of community health. 2012; 37(6):1127-35. http://dx.doi.org/10.1007/s10900-012-9554-z. PMID: 22426995.
31. Wamai RG, Ayissi CA, Oduwo GO, Perlman S, Welty E, Manga S, et al. Assessing the Effectiveness of a Community-Based Sensitization Strategy in Creating Awareness About HPV, Cervical Cancer and HPV Vaccine Among Parents in North West Cameroon. Journal of community health. 2012; 37(5):917-26. doi: 10.1007/s10900-012-9540-5. WOS:000308537100001. PMID: 22302651
32. Wamai RG, Ayissi CA, Oduwo GO, Perlman S, Welty E, Welty T, et al. Awareness, knowledge and beliefs about HPV, cervical cancer and HPV vaccines among nurses in Cameroon: An exploratory study. International Journal of Nursing Studies. 2013; 50(10):1399-406. http://dx.doi.org/10.1016/j.ijnurstu.2012.12.020. PMID: 23395482.
33. Ogembo JG, Manga S, Nulah K, Foglabenchi LH, Perlman S, Wamai RG, et al. Achieving high uptake of human papillomavirus vaccine in Cameroon: Lessons learned in overcoming challenges. Vaccine. 2014; 32(35):4399-403. Epub 2014/06/27. https://doi.org/10.1016/j.vaccine.2014.06.064 PMID: 24968154.
34. Manga S, Welty E, Welty T, Nulah K, Haritu L. Preventing cervical cancer through an HPV vaccine delivery project in cameroon. International Journal of Gynecological Cancer. 2014; 4:819-20.
35. Abarca V K, Valenzuela B MT, Vergara F R, Luchsinger F V, MunozM A, Jimenez de la J J, et al. Human papillomavirus vaccine. Statement of the Advisory Committee of Immunizations on Behalf of the Chilean Infectious Diseases Society. September 2008. Revista Medica de Chile. 2008; 136 (11):1485-92. PMID: 19301782.
36. Larson HJ, Brocard P, Garnett G. The India HPV-vaccine suspension. The Lancet. 2010; 376 (9741):572-3.
37. Tsu VD, Cernuschi T, LaMontagne DS. Lessons learned from HPV vaccine delivery in low-resource settings and opportunities for HIV prevention, treatment, and care among adolescents. J Acquir Immune Defic Syndr. 2014; 66 Suppl 2:S209-16. Epub 2014/06/12. https://doi.org/10.1097/qai.0000000000000175 PMID: 24918597.
38. LaMontagne DS, Barge S, Le NT, Mugisha E, Penny ME, Gandhi S, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bulletin of the World Health Organization. 2011; 89(11):821-30B. Epub 2011/11/16. https://doi.org/10.2471/BLT.11. 089862 PMID: 22084528;
39. Levin A, Wang SA, Levin C, Tsu V, Hutubessy R. Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries. PloS one. 2014; 9(6):e101114. Epub 2014/06/27. https://doi.org/10.1371/journal.pone.0101114 PMID: 24968002;
40. Sathyanarayana T, Hawkes S, Shahmanesh M, Laxminarayan R, Murthy GVS. Evidence, politics and cultures in policymaking: Policy analysis of HPV vaccine introduction in India. Sexually Transmitted Infections. 2015; 91:A61. http://dx.doi.org/10.1136/sextrans-2015-052270.166
41. Vermandere H, Naanyu V, Mabeya H, Broeck DV, Michielsen K, Degomme O. Determinants of acceptance and subsequent uptake of the HPV vaccine in a cohort in Eldoret, Kenya. PloS one. 2014; 9(10). http://dx.doi.org/10.1371/journal.pone.0109353.
42. Masika MM, Ogembo JG, Chabeda SV, Wamai RG, Mugo N. Knowledge on HPV vaccine and cervical cancer facilitates vaccine acceptability among school teachers in Kitui County, Kenya. PLoS ONE. 2015; 10 (8) (no pagination)(e0135563). http://dx.doi.org/10.1371/journal.pone.0135563.
43. Singh Y, Shah A, Singh M, Verma S, Shrestha BM, Vaidya P, et al. Human papilloma virus vaccination in Nepal: an initial experience in Nepal. Asian Pacific journal of cancer prevention: APJCP. 2010; 11 (3):615-7. Epub 2010/11/03. PMID: 21039025.
44. Bartolini RM, Winkler JL, Penny ME, LaMontagne DS. Parental Acceptance of HPV Vaccine in Peru: A Decision Framework. PloS one. 2012; 7(10). http://dx.doi.org/10.1371/journal.pone.0048017.
45. Penny M, Bartolini R, Mosqueira NR, LaMontagne DS, Mendoza MA, Ramos I, et al. Strategies to vaccinate against cancer of the cervix: Feasibility of a school-based HPV vaccination program in Peru. Vaccine. 2011; 29(31):5022-30. doi: 10.1016/j.vaccine.2011.04.078. WOS:000293043500020. PMID: 21609748
46. Levinson KL, Abuelo C, Chyung E, Salmeron J, Belinson SE, Sologuren CV, et al. The Peru Cervical Cancer Prevention Study (PERCAPS) Community-Based Participatory Research in Manchay, Peru. International Journal of Gynecological Cancer. 2013; 23(1):141-7. doi: 10.1097/IGC.0b013e318275b007. WOS:000314005000020. PMID: 23165314
47. Abuelo CE, Levinson KL, Salmeron J, Sologuren CV, Fernandez MJ, Belinson JL. The Peru Cervical Cancer Screening Study (PERCAPS): the design and implementation of a mother/daughter screen, treat, and vaccinate program in the Peruvian jungle. Journal of community health. 2014; 39(3):409-15. Epub 2013/11/28. https://doi.org/10.1007/s10900-013-9786-6 PMID: 24276617;
48. Levin CE, Van Minh H, Odaga J, Rout SS, Ngoc DN, Menezes L, et al. Delivery cost of human papillomavirus vaccination of young adolescent girls in Peru, Uganda and Viet Nam. Bulletin of the World Health Organization. 2013; 91(8):585-92. Epub 2013/08/14. https://doi.org/10.2471/BLT.12.113837 PMID: 23940406;
49. Vallejos-Sologuren C. The health minister's response to managing cervical cancer in low-income countries. Annals of Oncology. 2010; 21:viii41. http://dx.doi.org/10.1093/annonc/mdq511.
50. Binagwaho A, Ngabo F, Wagner CM, Mugeni C, Gatera M, Nutt CT, et al. Integration of comprehensive women's health programmes into health systems: Cervical cancer prevention, care and control in Rwanda Integration de programmes de soins complets pour les femmes dans les systemes de sante: Prevention, traitement et lutte contre le cancer du col de l'uterus au Rwanda. Bulletin of the World Health Organization. 2013; 91(9):697-703. http://dx.doi.org/10.2471/BLT.12.116087.
51. Ngabo F, Levin A, Wang SA, Gatera M, Rugambwa C, Kayonga C, et al. A cost comparison of introducing and delivering pneumococcal, rotavirus and human papillomavirus vaccines in Rwanda. Vaccine. 2015; 33(51):7357-63. http://dx.doi.org/10.1016/j.vaccine.2015.10.022. PMID: 26519548.
52. Torres-Rueda S, Rulisa S, Burchett HED, Mivumbi NV, Mounier-Jack S. HPV vaccine introduction in Rwanda: Impacts on the broader health system. Sexual and Reproductive Healthcare. 2016; 7:46-51. http://dx.doi.org/10.1016/j.srhc.2015.11.006. PMID: 26826045
53. Binagwaho A, Wagner CM, Gatera M, Karema C, Nutt CT, Ngabo F. Achieving high coverage in Rwanda's national human papillomavirus vaccination programme. Bulletin of the World Health Organization. 2012; 90(8):623-8. doi: 10.2471/BLT.11.097253.WOS:000307485500013. PMID: 22893746
54. Botha MH, Van Der Merwe FH, Snyman L, Dreyer G. The vaccine and cervical cancer screen (VACCS) project-acceptance of human papilloma virus vaccination in a school based program. International Journal of Gynecological Cancer. 2014; 4:821. http://dx.doi.org/10.1097/01.IGC.0000457075.08973.89
55. Dreyer G, Merwe FHvd, Botha MH, Snyman LC, Constant D, Visser C, et al. School-based human papillomavirus vaccination: an opportunity to increase knowledge about cervical cancer and improve uptake of screening. SAMJ South African Medical Journal. 2015; 105(11):912-6. http://dx.doi.org/10.7196/SAMJ.2015.v105i11.9814. PMID: 26632317.
56. Hoque M, Van Guido H. The knowledge about, beliefs and attitudes of medical students regarding vaccination against the human papillomavirus, in south africa: A Cross-Sectional study. Biomedical Research (India). 2015; 26(1):65-70.
57. Snyman LC, Dreyer G, Botha MH, Merwe FHvd, Becker PJ. The Vaccine and Cervical Cancer Screen (VACCS) project: linking cervical cancer screening to HPV vaccination in the South-West District of Tshwane, Gauteng, South Africa. SAMJ South African Medical Journal. 2015; 105(2):115-20. http://dx. doi.org/10.7196/samj.8418. PMID: 26242529.
58. Tathiah N, Naidoo M, Moodley I. Human papillomavirus (HPV) vaccination of adolescents in the South African private health sector: Lessons from the HPV demonstration project in KwaZulu-Natal. South African Medical Journal. 2015; 105(11):954. http://dx.doi.org/10.7196/SAMJ.2015.v105i11.10135. PMID: 26937512.
59. Botha MH, van der Merwe FH, Snyman LC, Dreyer G. The vaccine and cervical cancer screen (VACCS) project: acceptance of human papillomavirus vaccination in a school-based programme in two provinces of South Africa. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. 2015; 105(1):40-3. Epub 2015/06/06. PMID: 26046162.
60. Katz IT, Nkala B, Dietrich J, Wallace M, Bekker LG, Pollenz K, et al. A Qualitative Analysis of Factors Influencing HPV Vaccine Uptake in Soweto, South Africa among Adolescents and Their Caregivers. PloS one. 2013; 8(8). doi: 10.1371/journal.pone.0072094. WOS:000323880200008. PMID: 24023613
61. Moodley I, Tathiah N, Mubaiwa V, Denny L. High uptake of Gardasil vaccine among 9-12-year-old schoolgirls participating in an HPV vaccination demonstration project in KwaZulu-Natal Province, South Africa. Samj South African Medical Journal. 2013; 103(5):318-21. doi: 10.7196/samj.6414. WOS:000319721900023. PMID: 23971122
62. Hutubessy R, Levin A, Wang S, Morgan W, Ally M, John T, et al. A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool. BMC medicine. 2012; 10:136. Epub 2012/11/14. https://doi.org/10.1186/1741- 7015-10-136 PMID: 23146319;
63. Quentin W, Terris-Prestholt F, Changalucha J, Soteli S, Edmunds WJ, Hutubessy R, et al. Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania. BMC medicine. 2012; 10:137. http://dx.doi.org/10.1186/1741-7015-10-137. PMID: 23148516.
64. Watson-Jones D, Baisley K, Ponsiano R, Lemme F, Remes P, Ross D, et al. HPV vaccination in Tanzanian schoolgirls: cluster-randomised trial comparing two vaccine delivery strategies. Journal of Infectious Diseases. 2012:jis407.
65. Watson-Jones D, Changalucha J, Hayes R. Delivery, uptake and acceptability of HPV vaccination in Tanzanian girls: Final report and findings of the Mwanza Human Papillomavirus (HPV) Vaccination Project. Mwanza Intervention Trials Unit, National Institute for Medical Research Mwanza, London School of Hygiene and Tropical Medicine, Institute Catala d'Oncologia, Medical Research Council UK, World Health Organization, 2013.
66. Watson-Jones D, Tomlin K, Remes P, Baisley K, Ponsiano R, Soteli S, et al. Reasons for receiving or not receiving HPV vaccination in primary schoolgirls in Tanzania: a case control study. PloS one. 2012; 7(10):e45231. Epub 2012/11/02. https://doi.org/10.1371/journal.pone.0045231 PMID: 23115621;
67. Watson-Jones D, Lees S, Neke N, Mwanga J, Changalucha J, Ross D, editors. FEASIBILITY AND ACCEPTABILITY OF INTEGRATING ADOLESCENT HEALTH INTERVENTIONS WITH HPV VACCINATION IN TANZANIA. 29th International Papillomavirus Conference, HPV 2014; 2014; Washington, Seattle.
68. Watson-Jones D, Lees S, Mwanga J, Neke N, Changalucha J, Broutet N, et al. Feasibility and acceptability of delivering adolescent health interventions alongside HPV vaccination in Tanzania. Health policy and planning. 2016; 31(6):691-9. Epub 2016/01/16. https://doi.org/10.1093/heapol/czv119 PMID: 26768827;
69. Yothasamut J, Putchong C, Sirisamutr T, Teerawattananon Y, Tantivess S. Scaling up cervical cancer screening in the midst of human papillomavirus vaccination advocacy in Thailand. BMC health services research. 2010; 10 Suppl 1:S5. Epub 2010/07/16. https://doi.org/10.1186/1472-6963-10-s1-s5 PMID: 20594371;
70. Limpaphayom KK, Eamratsameekool W, Lu E. Implementing HPV vaccine to reach young girls in Thailand. Journal of Clinical Oncology. 2014; 1.
71. Aujo JC, Bakeera-Kitaka S, Kiguli S, Mirembe F. No difference in sexual behavior of adolescent girls following Human Papilloma Virus vaccination: a case study two districts in Uganda; Nakasongola and Luwero. BMC public health. 2014; 14:155. Epub 2014/02/14. https://doi.org/10.1186/1471-2458-14-155 PMID: 24520841;
72. Galagan SR, Paul P, Menezes L, LaMontagne DS. Influences on parental acceptance of HPV vaccination in demonstration projects in Uganda and Vietnam. Vaccine. 2013; 31(30):3072-8. doi: 10.1016/j. vaccine.2013.04.056. WOS:000321178800007. PMID: 23684835
73. Banura C, Mirembe FM, Katahoire AR, Namujju PB, Mbidde EK. Universal routine HPV vaccination for young girls in Uganda: a review of opportunities and potential obstacles. Infectious agents and cancer. 2012; 7(24).
74. Katagwa VN, Opio RO, Niwasasira DN, Onyege A, Naisanga M, Bongomin FA, et al. Acceptability of human papilloma virus vaccination among primary school girls in Minakulu sub-county, northern Uganda. Eur J Cancer Prev. 2014; 23(4):294-5. Epub 2014/05/30. https://doi.org/10.1097/CEJ. 0000000000000021 PMID: 24871561.
75. Katahoire AR, Wani JA, Murokora D, Mugisha E, LaMontagne DS. Acceptability of HPV vaccine among young adolescent girls in Uganda: Young people's perspectives count. International Journal of Child and Adolescent Health. 2013; 6(2):211.
76. Mugisha E, LaMontagne DS, Katahoire AR, Murokora D, Kumakech E, Seruyange R, et al. Feasibility of delivering HPV vaccine to girls aged 10 to 15 years in Uganda. African health sciences. 2015; 15 (1):33-41. https://doi.org/10.4314/ahs.v15i1.5 PMID: 25834528
77. Nakkazi E. Cancer vaccine boosted by infrastructure for HIV care in Africa. Nat Med. 2011; 17(3):272. Epub 2011/03/09. https://doi.org/10.1038/nm0311-272a PMID: 21383729.
78. Turiho AK, Okello ES, Muhwezi WW, Harvey S, Byakika-Kibwika P, Meya D, et al. Effect of schoolbased human papillomavirus (hpv) vaccination on adolescent girls' knowledge and acceptability of the HPV vaccine in Ibanda District in Uganda. African journal of reproductive health. 2014; 18(4):45-53. Epub 2015/04/10. PMID: 25854092;
79. Jain KM, Paul P, LaMontagne DS. Monitoring adverse events following immunisation in developing countries: experience from human papillomavirus vaccination demonstration projects. Sexual health. 2013; 10(1):57-63. doi: 10.1071/SH11161. WOS:000314926700009. PMID: 23237538
80. Turiho AK, Muhwezi WW, Okello ES, Tumwesigye NM, Banura C, Katahoire AR. Human papillomavirus (HPV) vaccination and adolescent girls' knowledge and sexuality in Western Uganda: A comparative cross-sectional study. PLoS ONE. 2015; 10 (9) (no pagination)(e0137094). http://dx.doi.org/10.1371/journal.pone.0137094.
81. Hasahya OT, Berggren V, Sematimba D, Nabirye RC, Kumakech E. Beliefs, perceptions and healthseeking behaviours in relation to cervical cancer: a qualitative study among women in Uganda following completion of an HPV vaccination campaign. Global health action. 2016; 9:29336. Epub 2016/02/20. https://doi.org/10.3402/gha.v9.29336 PMID: 26895145;
82. Cover JK, Nghi NQ, LaMontagne DS, Huyen DTT, Hien NT, Nga lT. Acceptance patterns and decisionmaking for human papillomavirus vaccination among parents in Vietnam: an in-depth qualitative study post-vaccination. BMC public health. 2012; 12(1):629.
83. LaMontagne DS, Nghi NQ, Nga le T, Janmohamed A, Huyen DT, Hien NT, et al. Qualitative study of the feasibility of HPV vaccine delivery to young adolescent girls in Vietnam: evidence from a government- implemented demonstration program. BMC public health. 2014; 14:556. Epub 2014/06/06. https://doi.org/10.1186/1471-2458-14-556 PMID: 24898950;
84. Paul P, LaMontagne DS, Le NT. Knowledge of cervical cancer and HPV vaccine post- vaccination among mothers and daughters in Vietnam. Asian Pacific journal of cancer prevention: APJCP. 2012; 13(6):2587-92. Epub 2012/09/04. PMID: 22938425.
85. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. International journal of surgery (London, England). 2010; 8(5):336-41. Epub 2010/02/23.
86. World Health Organization. Principles and considerations for adding a vaccine to a national immunization programme: from decision to implementation and monitoring. World Health Organization, 2014.
87. Kabakama S, Gallagher KE, Howard N, Mounier-Jack S, Burchett HED, Griffiths UK, et al. Social mobilisation, consent procedures, and acceptability: a study of human papillomavirus vaccination in low and middle-income countries. BMC public health. 2016; 9(16 (1)). https://doi.org/10.1186/s12889-016- 3517-8 PMID: 27543037
88. Strategic Advisory Group of Experts (SAGE) on Immunization W. Evidence based recommendations on Human Papilloma Virus (HPV) Vaccines Schedules: Background Paper for SAGE Discussions. World Health Organization, 2014 March 11 2014. Report No.
89. World Health Organization. Human Papillomavirus vaccines: WHO position paper October 2014. 2014.
90. PATH. Cervical Cancer Library-HPV vaccine lessons learnt. http://www.rho.org/HPVlessons. 2015 [cited 2015 30th November].